Nevertheless, up to 30–40% of NSCLC patients with high PDL1 expression exhibit primary resistance to therapy, and tumors with very low PDL1 expression can respond even without additional chemotherapy4. The gene discussed is CD274; the disease is non-small cell lung carcinoma.